SHL.DE

49.43

-0.96%↓

ARGX

486.6

+0.1%↑

VIE

29.94

+0.71%↑

BNR

63.94

-1.36%↓

GLPG

27.46

+2.39%↑

SHL.DE

49.43

-0.96%↓

ARGX

486.6

+0.1%↑

VIE

29.94

+0.71%↑

BNR

63.94

-1.36%↓

GLPG

27.46

+2.39%↑

SHL.DE

49.43

-0.96%↓

ARGX

486.6

+0.1%↑

VIE

29.94

+0.71%↑

BNR

63.94

-1.36%↓

GLPG

27.46

+2.39%↑

SHL.DE

49.43

-0.96%↓

ARGX

486.6

+0.1%↑

VIE

29.94

+0.71%↑

BNR

63.94

-1.36%↓

GLPG

27.46

+2.39%↑

SHL.DE

49.43

-0.96%↓

ARGX

486.6

+0.1%↑

VIE

29.94

+0.71%↑

BNR

63.94

-1.36%↓

GLPG

27.46

+2.39%↑

Inicio・Lista de Acciones・Sanofi SA

Sanofi SA

Cerrado

Sector Salud

103.3 0.33

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

102.84

Máximo

103.74

Métricas clave
By Trading Economics
Ingresos	1.1B
Ventas	916M 11B
P/B Media del Sector	24.91 103.001
BPA	1.73
Margen de beneficio	9.78
EBITDA	-136M 2B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+5.8 upside

Dividendos
By Dow Jones
Próximas Ganancias	25 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	131B
Apertura anterior	102.97
Cierre anterior	103.3

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

303 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

102.72 / 104.9 Soporte y Resistencia

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 sept 2024, 06:00 UTC

Adquisiciones, fusiones, absorciones

Santander Sells $634-Million Stake in Polish Subsidiary

25 jul 2024, 05:44 UTC

Ganancias

Sanofi Raises Guidance After Profit, Sales Beat

24 jul 2024, 10:24 UTC

Ganancias

Spanish Bank Santander Raises 2024 Guidance After Earnings Beat -- Update

24 jul 2024, 05:22 UTC

Ganancias

Santander Raises 2024 Revenue Guidance After Earnings Increase

4 jul 2024, 06:44 UTC

Adquisiciones, fusiones, absorciones

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27 jun 2024, 10:54 UTC

Principales Movimientos del Mercado

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

9 sept 2024, 07:56 UTC

Charlas de Mercado

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

15 ago 2024, 08:21 UTC

Charlas de Mercado

Ganancias

European Banks' Net Interest Income Momentum May Have Stalled -- Market Talk

14 ago 2024, 07:07 UTC

Charlas de Mercado

Southern European Banks Have Attractive Net Interest Income Dynamics -- Market Talk

26 jul 2024, 12:53 UTC

Charlas de Mercado

Ganancias

European Banks' Earnings Season Had Another Good Start -- Market Talk

25 jul 2024, 13:20 UTC

Ganancias

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25 jul 2024, 11:46 UTC

Charlas de Mercado

Ganancias

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25 jul 2024, 11:23 UTC

Charlas de Mercado

Ganancias

Sanofi Results Are Positive -- Market Talk

25 jul 2024, 05:33 UTC

Ganancias

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25 jul 2024, 05:33 UTC

Ganancias

Sanofi 2Q Sales EUR10.745B

25 jul 2024, 05:30 UTC

Ganancias

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25 jul 2024, 05:30 UTC

Ganancias

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25 jul 2024, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25 jul 2024, 05:30 UTC

Ganancias

Sanofi 2Q Net Pft EUR1.11B

25 jul 2024, 05:30 UTC

Ganancias

Sanofi Raises 2024 View

25 jul 2024, 05:30 UTC

Ganancias

Sanofi 2Q Business Operating Income EUR2.81B

24 jul 2024, 06:53 UTC

Charlas de Mercado

Ganancias

Santander's Small Beats, Improved Outlook Should Be Well Received -- Market Talk

24 jul 2024, 04:50 UTC

Ganancias

Santander Raises 2024 Rev View

24 jul 2024, 04:50 UTC

Ganancias

Santander Fully-Loaded CET1 Ratio 12.5% at 2Q-End

24 jul 2024, 04:48 UTC

Ganancias

Santander 2Q Net Interest Income Fell 4.2%

24 jul 2024, 04:48 UTC

Ganancias

Santander 2Q Net Interest Income EUR11.47B

24 jul 2024, 04:48 UTC

Ganancias

Santander 2Q Net Pft EUR3.21B

24 jul 2024, 04:47 UTC

Ganancias

Santander 2Q Rev EUR15.67B

9 jul 2024, 09:05 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3 jul 2024, 14:18 UTC

Adquisiciones, fusiones, absorciones

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

5.8% repunte

Estimación a 12 meses

Media 109.401 EUR 5.8%

Máximo 125 EUR

Mínimo 85 EUR

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Sanofi SA Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

102.72 / 104.9Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

303 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.